Bioethicist Arthur Caplan Questions FDA on Clinical Trial Status
What happened
In April 2006, Arthur Caplan questioned the FDA regarding the status of clinical trials. This occurred during a discussion about whether embryos left over from in vitro fertilization procedures should be used for stem-cell research that would result in the embryos' death.
From newsbusters.org
Why it matters
The questioning relates to the regulatory environment for stem-cell research and biotech. The FDA formally regulates the drug development and market activities of companies like Eli Lilly and Company, determining product viability and market access.
From newsbusters.org
Who's involved
- Arthur CaplanAmerican bioethicist who questioned the FDA regarding clinical trial status
- FDARegulatory agency that oversees drug development and clinical trials
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Eli Lilly and CompanySpeculative
Pharmaceutical companies might face changes in costs or market access depending on regulatory guidelines for stem-cell therapies.
Keep exploring
The entities involved
- FDA
-
Arthur Caplan
American bioethicist
Nothing else this week.
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- Litigation regarding FDA approval process.
- The Charlotte Lozier Institute found that the FDA lacked sufficient evidence in its review process.
- FDA approval expands patient access to therapies for ACCORD.